Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT Study of hepatitis B immunity preservation and transfer after non-myeloablative allogeneic HSCT in adult sickle cell disease
NL-OMON52342Terminated
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of Hepatitis B vaccine in sickle cell disease (SCD) (5 cohorts), sponsored by Amsterdam University Medical Center. Primary endpoint: Preserved anti-HBs response after matched sibling donor HSCT. Started Jul 2021; status: terminated.
02
Drugs
Hepatitis B vaccine
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NL-OMON52342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52342.